Abstract
No public abstract is available from the verified source records.
Maria Creignou, Elsa Bernard
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Germ line landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms
10.1182/bloodadvances.2026020704 · 2026
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022
International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
10.1038/s41375-020-0917-7 · 2021
Molecular international prognostic scoring system for myelodysplastic syndromes
10.1056/evidoa2200008 · 2022
Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers
10.1097/hs9.0000000000000632 · 2021
Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment
10.1158/2643-3230.bcd-24-0103 · 2024
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms
10.1136/jmedgenet-2011-100674 · 2012
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia
10.1002/cncr.29615 · 2016
Role of germline predisposition to therapy-related myeloid neoplasms
10.1007/s11899-022-00676-2 · 2022
No additional external references are available.